BridgeMD
New treatment option for Glucose Intolerance After a Recent History of Gestational Diabetes
Official title Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
ClinicalTrials.gov ID: NCT05569772
What this study is testing
What is Semaglutide Pen Injector?
Semaglutide Pen Injector is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for glucose intolerance after a recent history of gestational diabetes.
Also referred to as Ozempic.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Eligible participants are women aged ≥18 years, with a history of GDM diagnosed according to the 2013 WHO criteria (at 24-32 weeks gestation or \<24...
- Additional include cessation of breastfeeding, no intention to become pregnant within the next year, use of effective contraception and no use of...
You likely can't join if
- include established diabetes, presence of autoantibodies suggestive of type 1 diabetes, normal glucose tolerance, history of pancreatitis, previous...
The study team makes the final eligibility decision.
Where it's taking place
- Aalst, Belgium
- Antwerp, Belgium
- Bruges, Belgium
- Brussels, Belgium
- Ieper, Belgium
- Kortrijk, Belgium
- Leuven, Belgium
- Liège, Belgium
- Mouscron, Belgium
- Sint-Niklaas, Belgium
- Turnhout, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aalst, Belgium; Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium; Ieper, Belgium; Kortrijk, Belgium and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.